Paper41295464
A Multiplex Serological Assay to Evaluate the Antibody Responses to a Set of Plasmodium falciparum Antigens and Their Protective Role Against Malaria in Children Aged 1.5 to 12 Years Living in a Highly Seasonal Malaria Transmission Area of Burkina Faso.
Ezinmegnon S and 10 others. Vaccines (Basel), 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. A Multiplex Serological Assay to Evaluate the Antibody Responses to a Set of Plasmodium falciparum Antigens and Their Protective Role Against Malaria in Children Aged 1.5 to 12 Years Living in a Highly Seasonal Malaria Transmission Area of Burkina Faso. Papers, record 41295464. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41295464
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
A Multiplex Serological Assay to Evaluate the Antibody Responses to a Set of Plasmodium falciparum Antigens and Their Protective Role Against Malaria in Children Aged 1.5 to 12 Years Living in a Highly Seasonal Malaria Transmission Area of Burkina Faso.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36605129 | RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36605129 | PubMed |
| 2 | 37693871 | Analytical approaches for antimalarial antibody responses to confirm historical and recent malaria transmission: an example from the Philippines. | Lancet Reg Health West Pac | 2023 | https://conductscience.org/library/papers/37693871 | PubMed |
| 3 | 32127565 | Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination. | Sci Rep | 2020 | https://conductscience.org/library/papers/32127565 | PubMed |
| 4 | 38310910 | Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. | Lancet | 2024 | https://conductscience.org/library/papers/38310910 | PubMed |
| 5 | 37612716 | Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report. | Malar J | 2023 | https://conductscience.org/library/papers/37612716 | PubMed |
| 6 | 25927360 | Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175. | PLoS One | 2015 | https://conductscience.org/library/papers/25927360 | PubMed |
| 7 | 16515510 | Immune responses to asexual blood-stages of malaria parasites. | Curr Mol Med | 2006 | https://conductscience.org/library/papers/16515510 | PubMed |
| 8 | 28646586 | Vaccine candidate discovery for the next generation of malaria vaccines. | Immunology | 2017 | https://conductscience.org/library/papers/28646586 | PubMed |
| 9 | 23473542 | Influence of infection on malaria-specific antibody dynamics in a cohort exposed to intense malaria transmission in northern Uganda. | Parasite Immunol | 2013 | https://conductscience.org/library/papers/23473542 | PubMed |
| 10 | 35524310 | Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. | Malar J | 2022 | https://conductscience.org/library/papers/35524310 | PubMed |
| 11 | 23861883 | Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria. | PLoS One | 2013 | https://conductscience.org/library/papers/23861883 | PubMed |
| 12 | 20140214 | Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. | PLoS One | 2010 | https://conductscience.org/library/papers/20140214 | PubMed |
| 13 | 32972398 | Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia. | BMC Med | 2020 | https://conductscience.org/library/papers/32972398 | PubMed |
| 14 | 34357982 | Naturally Acquired Antibodies against Plasmodium falciparum: Friend or Foe? | Pathogens | 2021 | https://conductscience.org/library/papers/34357982 | PubMed |
| 15 | 34182772 | Protein Prenylation and Hsp40 in Thermotolerance of Plasmodium falciparum Malaria Parasites. | mBio | 2021 | https://conductscience.org/library/papers/34182772 | PubMed |
| 16 | 21949716 | A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720. | PLoS One | 2011 | https://conductscience.org/library/papers/21949716 | PubMed |
| 17 | 31849871 | Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines. | Front Microbiol | 2019 | https://conductscience.org/library/papers/31849871 | PubMed |
| 18 | 39018754 | Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum. | EBioMedicine | 2024 | https://conductscience.org/library/papers/39018754 | PubMed |
| 19 | 35141425 | 10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. | Wellcome Open Res | 2021 | https://conductscience.org/library/papers/35141425 | PubMed |
| 20 | 35198913 | Serological evaluation of the effectiveness of reactive focal mass drug administration and reactive vector control to reduce malaria transmission in Zambezi Region, Namibia: Results from a secondary analysis of a cluster randomised trial. | EClinicalMedicine | 2022 | https://conductscience.org/library/papers/35198913 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42093919 | Malaria antibody responses augment surveillance in low-transmission settings in the Upper River Region, the Gambia. | Front Epidemiol | 2026 | https://conductscience.org/library/papers/42093919 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DNAJB1P1 | 171221 | PubTator's text mining | https://conductscience.org/library/genes/171221 | NCBI Gene |
| DNAJC5 | 80331 | PubTator's text mining | https://conductscience.org/library/genes/80331 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41295464
GET https://conductscience.org/api/papers/v1/41295464/references?page=2